These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 37217243)
41. Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma. Santos-Briz A; Cañueto J; Carmen SD; Barrios B; Yuste M; Bellido L; Ludeña MD; Román C Am J Dermatopathol; 2021 Jun; 43(6):423-428. PubMed ID: 33395045 [TBL] [Abstract][Full Text] [Related]
42. Nivolumab for locally advanced and metastatic cutaneous squamous cell carcinoma (NIVOSQUACS study)-Phase II data covering impact of concomitant haematological malignancies. Lang R; Welponer T; Richtig E; Wolf I; Hoeller C; Hafner C; Nguyen VA; Kofler J; Barta M; Koelblinger P; Hitzl W; Emberger M; Laimer M J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1799-1810. PubMed ID: 37210651 [TBL] [Abstract][Full Text] [Related]
43. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. O'Byrne KJ; Lee KH; Kim SW; Park K; Nishio M; Sakai H; Ohe Y; Fukuhara T; Kang JH; Daga H; Yu CJ; Hotta K; Tanaka H; Takeda M; Yokoyama T; Nathan FE; Lee JS ESMO Open; 2022 Feb; 7(1):100394. PubMed ID: 35158207 [TBL] [Abstract][Full Text] [Related]
44. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992 [TBL] [Abstract][Full Text] [Related]
45. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Johnson DB; Bordeaux J; Kim JY; Vaupel C; Rimm DL; Ho TH; Joseph RW; Daud AI; Conry RM; Gaughan EM; Hernandez-Aya LF; Dimou A; Funchain P; Smithy J; Witte JS; McKee SB; Ko J; Wrangle JM; Dabbas B; Tangri S; Lameh J; Hall J; Markowitz J; Balko JM; Dakappagari N Clin Cancer Res; 2018 Nov; 24(21):5250-5260. PubMed ID: 30021908 [No Abstract] [Full Text] [Related]
46. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. Serra-Bellver P; Versluis JM; Oberoi HK; Zhou C; Slattery TD; Khan Y; Patrinely JR; Pires da Silva I; Martínez-Vila C; Cook N; Graham DM; Carlino MS; Menzies AM; Arance AM; Johnson DB; Long GV; Pickering L; Larkin JMG; Blank CU; Lorigan P Eur J Cancer; 2022 Nov; 176():121-132. PubMed ID: 36215945 [TBL] [Abstract][Full Text] [Related]
47. Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy. Iga N; Otsuka A; Hirata M; Kataoka TR; Irie H; Nakashima C; Matsushita S; Uchi H; Yamamoto Y; Funakoshi T; Fujisawa Y; Yoshino K; Fujimura T; Hata H; Ishida Y; Kabashima K Cancer Sci; 2019 Nov; 110(11):3434-3441. PubMed ID: 31509303 [TBL] [Abstract][Full Text] [Related]
48. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report. Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM Front Immunol; 2018; 9():2145. PubMed ID: 30283461 [No Abstract] [Full Text] [Related]
49. Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti-PD-1/PD-L1 Therapy. Carril-Ajuria L; Lora D; Carretero-González A; Martín-Soberón M; Rioja-Viera P; Castellano D; de Velasco G Clin Genitourin Cancer; 2021 Apr; 19(2):95-102. PubMed ID: 33189597 [TBL] [Abstract][Full Text] [Related]
50. Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: A propensity-matched real-world analysis. Torasawa M; Yoshida T; Yagishita S; Shimoda Y; Shirasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y Lung Cancer; 2022 May; 167():49-57. PubMed ID: 35397298 [TBL] [Abstract][Full Text] [Related]
51. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Motzer RJ; Powles T; Burotto M; Escudier B; Bourlon MT; Shah AY; Suárez C; Hamzaj A; Porta C; Hocking CM; Kessler ER; Gurney H; Tomita Y; Bedke J; Zhang J; Simsek B; Scheffold C; Apolo AB; Choueiri TK Lancet Oncol; 2022 Jul; 23(7):888-898. PubMed ID: 35688173 [TBL] [Abstract][Full Text] [Related]
52. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. Weber JS; Kudchadkar RR; Yu B; Gallenstein D; Horak CE; Inzunza HD; Zhao X; Martinez AJ; Wang W; Gibney G; Kroeger J; Eysmans C; Sarnaik AA; Chen YA J Clin Oncol; 2013 Dec; 31(34):4311-8. PubMed ID: 24145345 [TBL] [Abstract][Full Text] [Related]
53. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer). Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476 [TBL] [Abstract][Full Text] [Related]
54. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma. Saito R; Sawada Y; Nakamura M Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410 [TBL] [Abstract][Full Text] [Related]
55. Comparing the associations between host and tumor factors with survival outcomes with anti-PD-1 immunotherapy in metastatic melanoma. Koczka K; Rigo R; Batuyong E; Cook S; Asad M; Vallerand I; Suo A; Wang E; Cheng T Cancer Med; 2023 Feb; 12(3):2427-2439. PubMed ID: 35924450 [TBL] [Abstract][Full Text] [Related]
56. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557 [TBL] [Abstract][Full Text] [Related]
58. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. Ready N; Hellmann MD; Awad MM; Otterson GA; Gutierrez M; Gainor JF; Borghaei H; Jolivet J; Horn L; Mates M; Brahmer J; Rabinowitz I; Reddy PS; Chesney J; Orcutt J; Spigel DR; Reck M; O'Byrne KJ; Paz-Ares L; Hu W; Zerba K; Li X; Lestini B; Geese WJ; Szustakowski JD; Green G; Chang H; Ramalingam SS J Clin Oncol; 2019 Apr; 37(12):992-1000. PubMed ID: 30785829 [TBL] [Abstract][Full Text] [Related]
59. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma]. Liu HQ; Zou BQ; Wang SY Zhonghua Bing Li Xue Za Zhi; 2017 Nov; 46(11):782-788. PubMed ID: 29136692 [No Abstract] [Full Text] [Related]
60. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. Turiello R; Capone M; Morretta E; Monti MC; Madonna G; Azzaro R; Del Gaudio P; Simeone E; Sorrentino A; Ascierto PA; Morello S J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35273100 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]